Adalimumab Significantly Improves Quality of Life for Psoriasis Patients, Long-Term Study Finds
A new study reveals that long-term treatment with psoriasis/” title=”To the biological and systemic removal of …”>adalimumab offers significant and sustained improvements in work ability, daily activities, and overall quality of life for adults living with psoriasis.
Psoriasis, a chronic autoimmune disease, extends far beyond skin symptoms, profoundly impacting a patientS psychological well-being, social life, and daily functioning.Up to one in five individuals with psoriasis experience mental health challenges like depression and anxiety, regardless of disease severity. Now,research published in the Journal der Deutschen Dermatologischen Gesellschaft demonstrates the positive effects of this treatment over a five-year period. The study focused on real-world outcomes, moving beyond the controlled environments of traditional clinical trials. “Our study demonstrated in a large real-world population that long-term treatment of up to 5 years with adalimumab in adult patients with psoriasis led to a sustained advancement in the practice of professional and, in particular, nonprofessional activities,” researchers wrote.
The data revealed a significant decline in both psoriasis-related work absences and limitations in non-professional activities – such as hobbies, social engagements, and household tasks – among patients receiving adalimumab. At the start of the study, patients reported experiencing more limitations in their personal lives than in their work.
The Impact of Psoriasis on Daily Life
The study highlights the often-underestimated impact of psoriasis on non-professional activities. Researchers found a strong correlation between activity restrictions and factors like psoriatic arthritis, higher disease severity (measured by the Psoriasis area Severity Index [PASI] > 10), and a greater impairment in quality of life (assessed using the Dermatology Life Quality Index [DLQI] > 10).
while health-related quality of life improved over the observation period, it remained lower for those who continued to experience limitations in nonprofessional activities. This underscores the importance of addressing all facets of the disease, not just physical symptoms.
Study Limitations and Future Directions
The researchers acknowledged limitations inherent in the study’s design. As an observational, single-arm study, it lacked a control group, making it challenging to definitively rule out other contributing factors. Additionally, the reliance on real-world data and patient recall introduced potential for variability and bias.
Despite these caveats, the findings strongly suggest that adalimumab provides meaningful and lasting benefits for psoriasis patients. “restraint from nonprofessional activities affects well-being and appears to be an underestimated problem in patients with psoriasis, enhancing the burden of disease,” the researchers concluded. “Adalimumab treatment leads to a sustained and tangible improvement in daily nonprofessional activities of patients with psoriasis and their HRQOL [health-related quality of life]. It was shown for the first time that DLQI is highly associated with restraint from nonprofessional activities in a negative manner. This finding emphasizes the need for early intervention with efficacious therapies and holistic consideration of the social aspects in order to improve patients’ QOL [quality of life].”
References
- Kokolakis G, Philipp S, Mosch T, Fritz B, Sabat R. Impact of adalimumab treatment on impairment of non-professional activities in psoriasis patients. J Dtsch Dermatol Ges. Published online November 28, 2025. doi:10.1111/ddg.15949
- Steinzor P. Clinical severity may not correlate with psychological burden of psoriasis, study finds.AJMC®. May 7, 2025. Accessed December 1, 2025. https://www.ajmc.com/view/clinical-severity-may-not-correlate-with-psychological-burden-of-psoriasis-study-finds
